On 17 February 2016, orphan designation (EU/3/16/1617) was granted by the European Commission to Abbvie Ltd., United Kingdom, for venetoclax for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to AbbVie Deutschland GmbH & Co. KG, Germany, in May 2018.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2019 on request of the Sponsor.
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.